Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, BioMarin Pharmaceutical Inc. (BMRN) has a Wall Street consensus price target of $82.00, based on estimates from 40 covering analysts. With the stock currently trading at $61.73, this represents a potential upside of +32.8%. The company has a market capitalization of $11.86B.
Analyst price targets range from a low of $60.00 to a high of $104.00, representing a 54% spread in expectations. The median target of $84.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 27 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BMRN trades at a trailing P/E of 34.3x and forward P/E of 15.4x. Analysts expect EPS to grow +126.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $105.23, with bear and bull scenarios of $929.81 and $-369.68 respectively. Model confidence stands at 58/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BMRN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for BMRN is $82, representing 32.8% upside from the current price of $61.73. With 40 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BMRN has a consensus rating of "Buy" based on 40 Wall Street analysts. The rating breakdown is predominantly bullish, with 27 Buy/Strong Buy ratings. The consensus 12-month price target of $82 implies 32.8% upside from current levels.
With a forward P/E of 15.4487x, BMRN trades at a relatively low valuation. The consensus target of $82 implies 32.8% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $104 for BMRN, while the most conservative target is $60. The consensus of $82 represents the median expectation. Our quantitative valuation model projects a bull case target of $-370 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BMRN is heavily covered by Wall Street, with 40 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 27 have Buy ratings, 13 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BMRN stock forecast based on 40 Wall Street analysts shows a consensus price target of $82, with estimates ranging from $60 (bear case) to $104 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $105, with bear/bull scenarios of $930/$-370.
Our quantitative valuation model calculates BMRN's fair value at $105 (base case), with a bear case of $930 and bull case of $-370. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 58/100.
BMRN trades at a forward P/E ratio of 15.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 34.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on BMRN, with a "Buy" consensus rating and $82 price target (32.8% upside). 27 of 40 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BMRN analyst price targets range from $60 to $104, a 54% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $82 consensus represents the middle ground. Our model's $930-$-370 range provides an independent fundamental perspective.